Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00035024.xml
Thromb Haemost 2007; 98(01): 116-119
DOI: 10.1160/TH07-05-0364
DOI: 10.1160/TH07-05-0364
Anniversary Issue Contribution
Hirudin – the long and stony way from an anticoagulant peptide in the saliva of medicinal leech to a recombinant drug and beyond
A historical pieceFurther Information
Publication History
Received
22 May 2007
Accepted
23 May 2007
Publication Date:
29 November 2017 (online)
-
References
- 1 Wallis RB. Hirudin: From leeches to man. Sem Thromb Hemost 1996; 22: 185-196.
- 2 Müller IW. Handbuch der Blutegeltherapie. Heidelberg: Karl F Haug-Verlag; 2000
- 3 Haycraft JB. Über die Einwirkung eines Sekretes des officinellen Blutegels auf die Gerinnbarkeit des Blutes. Arch Exp Pathol Pharmakol 1884; 18: 209-217.
- 4 Blobel P. Versuche über Transfusion mit dem vom Blutegel gesogenen Blute und über die Verwen-dung frisch bereiteten Egeldecoctes zur Transfusion. Med. Dis. Greifswald 1892.
- 5 Jacobj C. Verfahren zur Darstellung des die Blutgerinnung aufhebenden Bestandtheiles des Blutegels. D. R. P., 1902; Patent Nr.136103, Klasse 30h/204.
- 6 Jacobj C. Über Hirudin. Dtsch Med Wochenschr 1904; 33: 1786-1787.
- 7 Morawitz P. Die Chemie der Blutgerinnung. Ergebn Physiol 1905; 4: 306-332.
- 8 Haas G. Dialysieren des strömenden Blutes am Lebenden. Klin Wochenschr 1923; 2: 1888.
- 9 Haas G. Versuche der Blutauswaschung am Lebenden mit Hilfe der Dialyse. Klin Wochenschr 1925; 4: 13-14.
- 10 Haas G. Über Blutwaschung. Klin Wochenschr 1928; 7: 1356-1362.
- 11 Haas G. Über die Fortschritte der Blutauswaschung am Lebenden mit Hilfe der Dialyse, zugleich eine Kritik über neuere die Blutgerinnung hemmende Mittel. Münch Med Wochenschr 1928; 75: 624.
- 12 Termier.. Traitement abortif des phlébites chirurgicales avec lever précoce. 31. Congrès francaisde Chirurgie. 1922. Presse médicale; Paris: 888.
- 13 Markwardt F. Die Isolierung und chemische Charakterisierung des Hirudins. Hoppe Seylers ZPhysiol Chem 1957; 308: 147-156.
- 14 Bodong A. Über Hirudin. Arch Exp Pathol Pharmakol 1905; 52: 242-261.
- 15 Baskova IP, Cherkesova DU, Mossolov VV. Purification of hirudin by isoelectric focusing. Biochimija 1976; 41: 939-941.
- 16 Baskova IP, Cherkesova DU, Mossolov VV. Hirudin from leech head and whole leech and “pseudo hirudin” from leech bodies. Thromb Res 1983; 30: 459-467.
- 17 Markwardt F, Walsmann P. Reindarstellung und Analyse des Thrombininhibitors Hirudin. Hoppe Seylers Z Physiol Chem 1967; 348: 1381-1386.
- 18 Petersen TE, Roberts HR, Sottrup-Jensen L. et al. Primary structure of hirudin, a thrombin-specific inhibitor. In: Peters H. (Ed.). Protides of the Biological Fluids. Vol 23 Pergamon Press; London/New York: 1976: 145-149.
- 19 Dodt J, Seemüller U, Maschler R. et al. The complete covalent structure of hirudin. Biol Chem Hoppe-Seyler 1985; 366: 379-385.
- 20 Gruetter MG, Priestle JP, Rahuel J. et al. Crystal structure of the thrombin-hirudin complex: A novel mode of serine protease inhibition. EMBO J 1990; 9: 2361-2365.
- 21 Fortkamp E, Rieger M, Heisterberg-Moutses G. et al. Cloning and expression in Escherichia coli of a synthetic DNA for hirudin, the blood coagulation inhibitor in the leech. DNA 1986; 5: 511-517.
- 22 Agnelli G, Pascussi C, Cosmi B. et al. The comparative effects of recombinant hirudin (CGP39393) and standard heparin on thrombus growth in rabbits. Thromb Haemost 1990; 63: 204-207.
- 23 Biemond BJ, Levi M, Nurmohamed MT. et al. Additive effect of the combined administration of low-molecular weight heparin and recombinant hirudinon thrombus growth in a rabbit jugular vein thrombosis model. Thromb Haemost 1994; 72: 377-380.
- 24 Glusa E, Markwardt F. Platelet functions in recombinant hirudin-anticoagulated blood. Haemostasis 1990; 20: 112-118.
- 25 Bretschneider E, Glusa E, Schrör K. ADP-, PAF and adrenaline-induced platelet aggregation and thromboxane formation are not affected by athromboxane receptor antagonist at physiological external Ca++ concentrations. Thromb Res 1994; 75: 233-242.
- 26 Markwardt F, Nowak G, Stürzebecher J. et al. Pharmacokinetics and anticoagulant effect of hirudinin man. Thromb Haemost 1984; 52: 160-163.
- 27 Markwardt F, Nowak G, Stürzebecher J. et al. Clinicopharmacological studies with recombinant hirudin. Thromb Res 1988; 52: 393-400.
- 28 Parent F, Bridey F, Dreyfus M. et al. Treatment of severe venous thromboembolism with intravenous hirudin (HBW 023): An open pilot study. Thromb Haemost 1993; 70: 386-388.
- 29 Eriksson BI, Kälebo P, Ekman S. et al. Direct thrombin inhibition with rec-hirudin CGP 39393 as prophylaxis of thromboembolic complications after hip replacement. Thromb Haemost 1994; 72: 227-231.
- 30 Yusuf S, Pogue J, Anand S. et al. on behalf of the OASIS-2 Investigators. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trial. Lancet 1999; 353: 429-438.